Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.78T
24h Vol:
$12.20B
Dominance:
MSFT:4.81%
Stocklytics Platform
Asset logo  SAGE
Sage Therapeutics
SAGE
68 / 100
$11.32arrow_drop_down6.44%-$0.78

Performance History

Stocklytics logo
Key Stats
Open$12.05
Prev. Close$12.10
EPS-8.39
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$672.83M
PE Ratio-
LOWHIGH
Day Range11.27
12.05
52 Week Range10.92
59.99
Ratios
P/B Ratio1.16
Revenue$86.45M
Operating M. %-1,489.18%
Earnings$0.00
Earnings Growth %-1.63%
EBITDA Margin %-586.74%
ROE %-54.72%
EPS-8.39

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$808.45
24H (%)arrow_drop_up0.69%
24H ($)$5.54
MARKET CAP$744.33B
PRICE$516.83
24H (%)arrow_drop_down0.86%
24H ($)-$4.51
MARKET CAP$476.05B
PRICE$149.70
24H (%)arrow_drop_down2.47%
24H ($)-$3.80
MARKET CAP$364.05B
PRICE$131.09
24H (%)0.00%
24H ($)-$0.01
MARKET CAP$332.27B

About Sage Therapeutics (SAGE)

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone, a neuroactive steroid, which has completed Phase III clinical trials for treating PPD and major depressive disorders, as well as is in Phase II clinical trials for treatment resistant depression, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Barry E. Greene
Headquarters
Cambridge
Employees
689
Exchange
NASDAQ
add Sage Therapeutics  to watchlist

Keep an eye on Sage Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Sage Therapeutics 's (SAGE) price per share?

The current price per share for Sage Therapeutics (SAGE) is $11.32. The stock has seen a price change of -$0.78 recently, indicating a -6.45% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Sage Therapeutics (SAGE)?

For Sage Therapeutics (SAGE), the 52-week high is $59.99, which is 429.95% from the current price. The 52-week low is $10.92, the current price is 3.66% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Sage Therapeutics (SAGE) a growth stock?

Sage Therapeutics (SAGE) has shown an average price growth of 0.41% over the past three years. It has received a score of 19 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Sage Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Sage Therapeutics (SAGE) stock price performance year to date (YTD)?

As of the latest data, Sage Therapeutics (SAGE) has a year-to-date price change of -49.64%. Over the past month, the stock has experienced a price change of -17.31%. Over the last three months, the change has been -49.98%. Over the past six months, the figure is -40.76%. Looking at a longer horizon, the five-year price change stands at -93.51%.

help
Is Sage Therapeutics (SAGE) a profitable company?

Sage Therapeutics (SAGE) has a net income of -$541.49M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.49K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $86.46M, although specific revenue growth data is currently not available. The gross profit is $84.3M. Operating income is noted at -$579.85M. Furthermore, the EBITDA is -$507.26M.

help
What is the market capitalization of Sage Therapeutics (SAGE)?

Sage Therapeutics (SAGE) has a market capitalization of $672.83M. The average daily trading volume is 1.48M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level